Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 In an ... the UPMC Center for Health Security review the clinical ... can be used as bioweapons. The article, "Clinical Management ... today on the website of the New England ... Adalja, Eric Toner , and Tom Inglesby—review the ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Follow us on LinkedIn ... fastest growing technologies in the life sciences industry. Growing ... driving growth in nucleic acid detection technologies like qPCR ... expressions will continue to benefit the qPCR and dPCR ... from pharma, biotech, food & beverage to animal feed, ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... 2012 Amgen (NASDAQ: AMGN ) and ... that the companies have entered into a definitive merger ... company founded in Germany with its research and development ... for $11 per share in cash. The transaction, which ...
... (NASDAQ: SQNM ) today announced the completion of ... stock, including 1,950,000 shares sold pursuant to the full exercise ... of the shares were offered by Sequenom at a price ... to Sequenom from this offering were approximately $62.0 million, before ...
... Corporation (NPC) and Sanford Wittels & Heisler, LLP, Counsel to ... resolve the nationwide Wage and Hour class action against NPC ... District of New York.  NPC has agreed ... up to 99 million dollars for eligible class members.  This ...
Cached Biology Technology:Amgen to Acquire Micromet 2Amgen to Acquire Micromet 3Amgen to Acquire Micromet 4Amgen to Acquire Micromet 5Amgen to Acquire Micromet 6Amgen to Acquire Micromet 7Amgen to Acquire Micromet 8Amgen to Acquire Micromet 9Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 2Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... For his creative work in evolutionary systems biology, Jeff ... Technology, is The Pew Charitable Trusts, biomedical researcher of the month. Gore ... the goal of understanding how pathogens become resistant to drugs. ... Inspired ...
... is available in German . ... previously assumed. More precise tests may allow allergy sufferers more freedom ... studies carried out by the Helmholtz Centre for Environmental Research (UFZ), ... The researchers examined patients with a Nile perch allergy. Being allergic ...
... on the biochemical makeup of small interfering RNA ... used in research to help scientists better understand ... accessible to researchers worldwide increases the potential of ... National Center for Advancing Translational Sciences (NCATS) collaborated ...
Cached Biology News:Each food fish can cause specific allergies 2Each food fish can cause specific allergies 3Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
Sf21 Insect Cells (Live) in Max-XP Medium...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... unit is an inexpensive personal or mini thermal ... process. Lightweight, with a small footprint, it can ... the researcher's desk. , The Gene Cycler thermal ... not have access to a large laboratory thermal ...
Biology Products: